Log in

NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Forecast & News

$4.27
+0.08 (+1.91 %)
(As of 01/27/2020 03:45 AM ET)
Today's Range
$4.10
Now: $4.27
$4.29
50-Day Range
$3.27
MA: $3.80
$4.79
52-Week Range
$1.39
Now: $4.27
$6.50
Volume3.62 million shs
Average Volume5.29 million shs
Market Capitalization$716.51 million
P/E RatioN/A
Dividend YieldN/A
Beta3.01
Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.19 million
Book Value$1.70 per share

Profitability

Net Income$-203,540,000.00
Net Margins-1,101.69%

Miscellaneous

Employees382
Market Cap$716.51 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.


Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics Inc (NASDAQ:SRNE) released its quarterly earnings data on Friday, November, 8th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.42). The biopharmaceutical company had revenue of $5.78 million for the quarter, compared to the consensus estimate of $7.70 million. Sorrento Therapeutics had a negative net margin of 1,101.69% and a negative return on equity of 193.12%. View Sorrento Therapeutics' Earnings History.

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Sorrento Therapeutics.

What price target have analysts set for SRNE?

3 brokers have issued 1-year price targets for Sorrento Therapeutics' stock. Their forecasts range from $12.00 to $30.00. On average, they expect Sorrento Therapeutics' stock price to reach $21.00 in the next year. This suggests a possible upside of 391.8% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.

What is the consensus analysts' recommendation for Sorrento Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.

Has Sorrento Therapeutics been receiving favorable news coverage?

News articles about SRNE stock have trended extremely negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sorrento Therapeutics earned a news impact score of -4.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Sorrento Therapeutics.

Who are some of Sorrento Therapeutics' key competitors?

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Amarin (AMRN), Micron Technology (MU), Cara Therapeutics (CARA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Viking Therapeutics (VKTX) and Canopy Growth (CGC).

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)
  • Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)
  • Mr. George K. Ng, Corp. Sec. (Age 45)
  • Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)
  • Ms. Deborah H. Telman, Sr. VP & Gen. Counsel

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Donald L. Hagan LLC (0.01%), Alpine Global Management LLC (0.01%) and Pegasus Asset Management Inc. (0.01%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd and George K Ng. View Institutional Ownership Trends for Sorrento Therapeutics.

Which major investors are buying Sorrento Therapeutics stock?

SRNE stock was bought by a variety of institutional investors in the last quarter, including Donald L. Hagan LLC, Alpine Global Management LLC and Pegasus Asset Management Inc.. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $4.27.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $716.51 million and generates $21.19 million in revenue each year. The biopharmaceutical company earns $-203,540,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.View Additional Information About Sorrento Therapeutics.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is http://www.sorrentotherapeutics.com/.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]


MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  501 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  811
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel